These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
245 related items for PubMed ID: 28718515
1. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Liu X, Ma Q, Zhao Y, Mu W, Sun X, Cheng Y, Zhang H, Ma Y, Zhang F. Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515 [Abstract] [Full Text] [Related]
2. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. Gupta SK, Rosenkranz SL, Cramer YS, Koletar SL, Szczech LA, Amorosa V, Hall SD. AIDS; 2008 Oct 01; 22(15):1919-27. PubMed ID: 18784455 [Abstract] [Full Text] [Related]
3. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya. Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA. PLoS One; 2022 Oct 01; 17(3):e0260872. PubMed ID: 35235559 [Abstract] [Full Text] [Related]
4. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection. Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W. PLoS One; 2015 Oct 01; 10(6):e0130583. PubMed ID: 26107645 [Abstract] [Full Text] [Related]
5. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study. Reay R, Dandara C, Viljoen M, Rheeders M. OMICS; 2017 Aug 01; 21(8):465-473. PubMed ID: 28816644 [Abstract] [Full Text] [Related]
6. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, Shao Y, Li J, Ye J, Scott SR, Mahajan SD, Schwartz SA, Yu H, Sun L. Curr HIV Res; 2019 Aug 01; 17(5):324-334. PubMed ID: 31654514 [Abstract] [Full Text] [Related]
7. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. Pharmacogenet Genomics; 2013 Aug 01; 23(8):415-27. PubMed ID: 23778320 [Abstract] [Full Text] [Related]
8. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Sukasem C, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, Prommas S, Chantratita W, Manosuthi W. Drug Metab Pharmacokinet; 2013 Aug 01; 28(5):391-7. PubMed ID: 23399569 [Abstract] [Full Text] [Related]
9. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Murnane PM, Strehlau R, Shiau S, Patel F, Mbete N, Hunt G, Abrams EJ, Coovadia A, Kuhn L. Clin Infect Dis; 2017 Aug 01; 65(3):477-485. PubMed ID: 28419200 [Abstract] [Full Text] [Related]
10. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G. Br J Clin Pharmacol; 2010 Jan 01; 69(1):95-8. PubMed ID: 20078617 [Abstract] [Full Text] [Related]
11. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW. Br J Clin Pharmacol; 2015 Jul 01; 80(1):146-56. PubMed ID: 25611810 [Abstract] [Full Text] [Related]
12. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. Gleason RL, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W. PLoS One; 2015 Jul 01; 10(4):e0117125. PubMed ID: 25915208 [Abstract] [Full Text] [Related]
13. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico. Ortíz-Rodríguez MA, Oaxaca-Navarro J, Patiño-Camacho SI, García-Jiménez S, Déciga-Campos M, Martínez-Salazar MF. Pharmazie; 2022 Jun 01; 77(6):191-195. PubMed ID: 35751161 [Abstract] [Full Text] [Related]
14. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Bienvenu E, Swart M, Dandara C, Ashton M. Antiviral Res; 2014 Feb 01; 102():44-53. PubMed ID: 24316028 [Abstract] [Full Text] [Related]
15. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. Ther Drug Monit; 2011 Aug 01; 33(4):417-24. PubMed ID: 21743379 [Abstract] [Full Text] [Related]
16. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V, MONOD Study Group. BMC Med; 2017 Apr 24; 15(1):85. PubMed ID: 28434406 [Abstract] [Full Text] [Related]
17. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia. Gleason RL, Caulk AW, Seifu D, Rosebush JC, Shapiro AM, Schwartz MH, Eckard AR, Amogne W, Abebe W. J Biomech; 2016 Sep 06; 49(13):2584-2592. PubMed ID: 27270208 [Abstract] [Full Text] [Related]
18. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D. Pediatr Infect Dis J; 2009 Feb 06; 28(2):159-61. PubMed ID: 19106779 [Abstract] [Full Text] [Related]
19. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V. Antivir Ther; 2009 Feb 06; 14(3):315-20. PubMed ID: 19474465 [Abstract] [Full Text] [Related]
20. Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. Egaña-Gorroño L, Martínez E, Domingo P, Loncà M, Escribà T, Fontdevila J, Vidal F, Negredo E, Gatell JM, Arnedo M. Antimicrob Agents Chemother; 2014 Nov 06; 58(11):6717-23. PubMed ID: 25155608 [Abstract] [Full Text] [Related] Page: [Next] [New Search]